Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.

Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.

Item
http://www.wikidata.org/entity/Q34450295
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in SchizophreniaGender-based personalized pharmacotherapy: a systematic review.Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerThe Protective Effect of Alpha 7 Nicotinic Acetylcholine Receptor Activation on Critical Illness and Its MechanismNatural compounds interacting with nicotinic acetylcholine receptors: from low-molecular weight ones to peptides and proteins.Potential serotonergic agents for the treatment of schizophrenia.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.Targeting α7 nicotinic acetylcholine receptors: a future potential for neuroprotection from traumatic brain injury.The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.
P2860

Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.

Item
http://www.wikidata.org/entity/Q34450295
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@ast
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@en
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@nl
type
label
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@ast
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@en
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@nl
prefLabel
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@ast
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@en
Pharmacodynamics, pharmacokine ...... e and bioavailability studies.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
Pharmacodynamics, pharmacokine ...... se and bioavailability studies
@en
P2093
P304
P31
P356
10.1016/J.CLINTHERA.2014.09.013
P433
P478
P50
P577
P5875
P698